ERBB2 and cancer: The frequency of human epidermal growth factor receptor 2 (HER2)–expressing gastric/gastroesophageal junction (G/GEJ) cancer was comparable between patients evaluated for targeted therapy in Japan (21.2%) versus worldwide, including Europe and the United States (20–22.1%) [4–6].